代谢危险因素风险分层及他汀类药物使用与慢性乙型肝炎患者肝脏和非肝脏结局的关联
美国全国性回顾性队列研究纳入52 277例慢性乙型肝炎患者,经1:1倾向评分匹配得到16 696对有无代谢危险因素的患者。糖尿病合并其余3项代谢危险因素者肝脏结局风险最高,aHR为2.08(95%CI 1.22-3.52);低代谢负担(≤2项)者使用他汀与肝脏结局风险降低相关。
要点
- 慢性乙型肝炎患者代谢负担越高,肝脏和非肝脏并发症风险越大,糖尿病影响最大。
- 糖尿病合并其余3项代谢危险因素者肝脏结局aHR为2.08(95%CI 1.22-3.52)。
- 低代谢负担(≤2项代谢危险因素)者使用他汀与任何肝脏结局风险降低15%相关。
核心结论
- 慢性乙型肝炎患者代谢负担越高,肝脏和非肝脏并发症风险越大,其中糖尿病在各项代谢危险因素中影响最大。
- 在低代谢负担(≤2项代谢危险因素)患者中,他汀使用与肝脏结局风险降低相关。
研究设计与样本
- 美国全国性回顾性队列研究,使用MarketScan数据库(2007年1月至2021年12月)纳入成人慢性乙型肝炎患者。
- 共纳入52 277例慢性乙型肝炎患者,经1:1倾向评分匹配得到16 696对有无代谢危险因素的患者进行分析。
- 代谢危险因素包括糖尿病、高血压、高脂血症和肥胖。
主要发现
- 与无代谢危险因素者相比,糖尿病合并其余3项代谢危险因素者任何肝脏结局的调整风险比最高,为2.08(95%CI 1.22-3.52)。
- 糖尿病合并其余3项代谢危险因素者心血管疾病调整风险比为12.98(95%CI 7.73-21.80),慢性肾脏病为9.25(95%CI 5.46-15.66),肝外癌症为2.01(95%CI 1.00-4.04)。
- 代谢负担增加与肝脏和非肝脏结局相关,但无代谢危险因素者与有代谢危险因素但无糖尿病者比较,所有肝脏结局P > .2。
- 在低代谢负担(≤2项代谢危险因素)患者中,他汀使用与任何肝脏结局风险降低15%相关,与肝细胞癌风险降低35%相关,与肝硬化风险降低15%相关;在高代谢负担(≥3项代谢危险因素)患者中未见此关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We investigated the association of metabolic risk factors (MRFs) and statin use with liver and nonliver outcomes in a nationwide cohort of patients with chronic hepatitis B (CHB) in the United States. METHODS: We conducted a retrospective cohort study of adult patients with CHB using the MarketScan Databases (January 2007-December 2021). Incidence of liver and nonliver outcomes (cardiovascular disease, chronic kidney disease, and extrahepatic cancer) was analyzed. MRFs included diabetes mellitus (DM), hypertension, hyperlipidemia, and obesity. RESULTS: The study included 52 277 patients with CHB, and 1:1 propensity score matching yielded 16 696 pairs of matched patients with and without MRFs for analysis. When compared with those without MRFs, patients with DM and all 3 other MRFs had the highest adjusted hazard ratio (95% CI) for any liver outcome at 2.08 (1.22-3.52), followed by 12.98 (7.73-21.80) for cardiovascular disease, 9.25 (5.46-15.66) for chronic kidney disease, and 2.01 (1.00-4.04) for extrahepatic cancer. Increased metabolic burden was associated with liver and nonliver outcomes except for comparison between patients without MRFs and those with MRFs but no DM (P > .2 for all liver outcomes). Among lower metabolic burden (≤2 MRFs), statin use was associated with a 15% lower risk of any liver outcomes, 35% reduced risk of HCC, and 15% lower risk of cirrhosis but not among those with higher metabolic burden (≥3 MRFs). CONCLUSIONS: Higher metabolic burden was associated with a greater risk for liver and nonliver complications in patients with CHB, with DM having the highest impact among other MRFs. Statin use was associated with a reduced risk of liver outcomes among lower metabolic burden.
引用
- Zhang X, Nguyen VH, Kam LY, et al. Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B. J Infect Dis. 2025. PMID: 39663709. doi:10.1093/infdis/jiae522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。